RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients

被引：3
|
作者：
Singh, Dave
Banner, Kathy
Newman, Kenneth
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2016年 / 48卷
关键词：
Bronchodilators; COPD; -; management; Anti-inflammatory;
D O I：
10.1183/13993003.congress-2016.PA4052
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA4052
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Safety, Tolerability And Pharmacokinetic Profile Of Chf6001, A Novel Selective Inhaled Pde4 Inhibitor, In Healthy Volunteers
    Nandeuil, M. -A.
    Mariotti, F.
    Lucci, G.
    Santoro, D.
    Poli, G.
    Acerbi, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [42] Safety, Tolerability and Pharmacokinetics of The Phosphodiesterase 3/4 (PDE3/4) Inhibitor TQC3721 Suspension for Inhalation in Healthy Adult Subjects
    Luo, Zhu
    Yang, Ling
    Jiang, Miao
    Yu, Ding
    Li, Weimin
    Li, Weiguo
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [43] An inhaled "bifunctional" dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD
    Cazzola, Mario
    Page, Clive
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52 (05)
  • [44] Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Improved Dyspnea in Subjects With Symptomatic, Moderate-to-Severe COPD Over 24 Weeks
    Mahler, D. A.
    Bhatt, S. P.
    Singh, D.
    Rheault, T.
    Reyner, D.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [45] Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, provides effective bronchodilation when administered by dry powder inhaler in COPD
    Rheault, Tara
    Boscia, Joseph A.
    Maurer, Brian
    Rickard, Kathleen
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [46] ENSIFENTRINE, A DUAL PDE 3 AND 4 INHIBITOR, PROVIDES EFFECTIVE BRONCHODILATION IN PATIENTS WITH COPD WHEN ADMINISTERED TWICE DAILY OVER 7 DAYS VIA PMDI
    Rheault, Tara
    Singh, Dave
    Leaker, Brian
    Bengtsson, Thomas
    Rickard, Kathleen
    CHEST, 2021, 160 (04) : 1847A - 1848A
  • [47] Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Reduced Moderate/Severe Exacerbation Rate and Risk in Subjects With COPD Regardless of Baseline Blood Eosinophils
    Sciurba, F. C.
    Christenson, S.
    Rheault, T.
    Reyner, D.
    Bengtsson, T.
    Rickard, K.
    Barjaktarevic, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [48] A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
    Ferguson, Gary T.
    Kerwin, Edward M.
    Rheault, Tara
    Bengtsson, Thomas
    Rickard, Kathleen
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 16 : 1137 - 1148
  • [49] Ibudilast, a mixed PDE3/4 inhibitor, causes a selective and nitric oxide/cGMP-independent relaxation of the intracranial vertebrobasilar artery
    Yamazaki, Takanobu
    Anraku, Tsuyoshi
    Matsuzawa, Shigeki
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 650 (2-3) : 605 - 611
  • [50] Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients
    Singh, Dave
    Govoni, Mirco
    Bassi, Michele
    Beeh, Kai Michael
    Colgan, Brendan
    Kornmann, Oliver
    Laeker, Brian
    Watz, Henrik
    Lucci, Germano
    Geraci, Silvia
    Rocco, Emanuele Calabro
    Emirova, Aida
    Nandeuil, Marie Anna
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
12345